Lu177-DOTA-octreotate therapy on neuroendocrine tumour management: A case report and literature review
Keywords:Peptide receptor radionuclide therapy (PRRT), Lu177-DOTA-octreotate, Neuroendocrine tumors (NET).
Favourable outcomes of peptide receptor radiotherapy of neuroendocrine tumors have been reported during the last years. This case report refers to a patient with a non-functional neuroendocrine carcinoma of pancreas with liver metastases and abdominal lymph nodes involvement. He underwent fractionated treatment with 4 cycles of Lu177-DOTA-octreoate (7.400MBq) after the failure of treatment with chemotherapy regiments. We conclude that fractionated therapy with Lu177-DOTA-octreotate should be considered a treatment option in the management of patients for symptomatic improvement in inoperable or metastasized neuroendocrine tumors, and for patients with large tumors and high somatostatin receptor expression.
LicenseAuthors who publish with this journal agree to the following terms:
a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).